TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16012271

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40 to 80 mg BID)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202
Study: 12602375

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epoetin alfa and beta
Number of subjects: 0
Study: 9856370

Group type: EXPERIMENTAL
Intervention: Lisinopril at 20 mg with the addition of 12.5 or 25 mg hydrochlorothiazide as needed
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (during final study month)
Number of subjects: 174
Study: 7619769

Group type: EXPERIMENTAL
Intervention: Trilostane
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 112
Study: 2797545

Group type: EXPERIMENTAL
Intervention: Fluoride rinse (0.2 percent sodium fluoride solution)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 273
Study: 344898

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone (repeated weekly treatment)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Intermittent treatment of the same five drugs given in 5‐day courses every 4 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Adriamycin as a single agent (treatment every 3 weeks)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Non-Caucasian patients
Number of subjects: 281

Group type: COMPARATOR
Intervention: Caucasian patients
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Ambulatory patients with long disease-free intervals and no liver involvement
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Remaining covariates (menopausal status, bone involvement, number of metastatic sites, duration of metastatic disease)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Treatment effect
Number of subjects: 281
Study: 29935152

Group type: EXPERIMENTAL
Intervention: Comprehensive training program (n=51)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Self-directed program (n=53)
Number of subjects: 104
Study: 28504067

Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise plus TrP dry needling (DN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual therapy and exercises
Number of subjects: 60
Study: 26126684

Group type: EXPERIMENTAL
Intervention: Acute exercise (1.5 h at 50% V̇o2 max)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subset of sphingomyelin species (C14:0, C22:3, C24:4)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Basal serum levels
Number of subjects: 3
Study: 23776118

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Darbe) 10 μg/kg, 1 time per week subcutaneously
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 400 U/kg, 3 times per week subcutaneously
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (sham dosing)
Number of subjects: 102
Study: 20929555

Group type: EXPERIMENTAL
Intervention: Usual care + brief 2-session psychological intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 19036233

Group type: EXPERIMENTAL
Intervention: 200 mg/day of quetiapine fumarate
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 400 mg/day of quetiapine fumarate
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Flexible dosing in Part 2
Number of subjects: 141
Study: 15737443

Group type: EXPERIMENTAL
Intervention: Gravity inversion position
Number of subjects: 22

Group type: COMPARATOR
Intervention: Chronic low-back pain group
Number of subjects: 22
Study: 12975010

Group type: EXPERIMENTAL
Intervention: Agrippal
Number of subjects: 499

Group type: COMPARATOR
Intervention: Flurix
Number of subjects: 499
Study: 10534145

Group type: EXPERIMENTAL
Intervention: Didanosine and stavudine (100 + 10 mg, 100 + 20 mg, 100 + 40 mg, 200 + 20 mg, and 200 + 40 mg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: High-dose subgroup (arms 3, 4, and 5)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination therapy (didanosine and stavudine)
Number of subjects: 86
Study: 8762780

Group type: EXPERIMENTAL
Intervention: Keeler Pulsair 2000
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: American Optical MkII
Number of subjects: 45

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 45
Study: 1817622

Group type: EXPERIMENTAL
Intervention: Verapamil 0.01 mg kg‐1 h‐1 (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (n = 13)
Number of subjects: 25
Study: 6983207

Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation (UVR) once a week for three months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oral vitamin D2 (450 IU) with 420 mg calcium daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calcium alone (420 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study: 30597503

Group type: EXPERIMENTAL
Intervention: Adjusted dose of enoxaparin according to anti-factor Xa levels
Number of subjects: 88

Group type: COMPARATOR
Intervention: Fixed dose of 40 mg daily LMWH
Number of subjects: 88
Study: 29018949

Group type: EXPERIMENTAL
Intervention: Metronome-paced strength training (MPST)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Self-paced strength training (SPST)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Skill training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 26445532

Group type: EXPERIMENTAL
Intervention: 250 mg Polygonum minus extract (PM) taken twice daily for 6 weeks
Number of subjects: 35
Study: 24268874

Group type: EXPERIMENTAL
Intervention: Isometric training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isotonic training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 22425113

Group type: COMPARATOR
Intervention: Placebo treatment with sham escalation
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo escalators
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo nonescalators
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 435
Study: 19092364

Group type: EXPERIMENTAL
Intervention: Cytokine therapy (granulocyte colony-stimulating factor, erythropoietin, and stem cell factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokine therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various combinations of cytokines with or without stem cell therapy
Number of subjects: 0
Study: 17297068

Group type: EXPERIMENTAL
Intervention: Training + Incentive (TI)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Training + Medication (TM)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Training + Incentive + Medication (TI+TM)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 577
Study: 15596181

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard hydration and diclofenac sodium
Number of subjects: 78
Study: 11080399

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard laparoscopic surgery (SLS)
Number of subjects: 40
Study: 9058557

Group type: EXPERIMENTAL
Intervention: Supportive-expressive (SE) therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cognitive therapy (CT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Individual drug counseling (IDC)
Number of subjects: 32
Study: 8354729

Group type: EXPERIMENTAL
Intervention: ePTFE plus DFDBA (experimental)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DFDBA alone (control)
Number of subjects: 15
Study: 3731684

Group type: EXPERIMENTAL
Intervention: prazosin (1 mg t.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 31391133

Group type: EXPERIMENTAL
Intervention: e‐health program providing diet, physical activity and well‐being advice over 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 57
Study: 30428513

Group type: EXPERIMENTAL
Intervention: Tabby Improved Prevention and Intervention Program (TIPIP)
Number of subjects: 759

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 759
Study: 26999688

Group type: EXPERIMENTAL
Intervention: Antioxidants (1 gram L-ascorbic acid per day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 200
Study: 25128278

Group type: EXPERIMENTAL
Intervention: Rapid Palatal Expansion (RPE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Slow Palatal Expansion (SPE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both RPE and SPE
Number of subjects: 20
Study: 22921557

Group type: EXPERIMENTAL
Intervention: Home-based cyclergometer training (30 min/day for 3 months, with monthly-supervised sessions)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study: 20368021

Group type: EXPERIMENTAL
Intervention: Early air drainage (< 72 h)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Delayed air drainage (> 6 d)
Number of subjects: 242
Study: 18711762

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan (TJQ) exercise, 1 hour per day, 5 days a week for 14 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 16400783

Group type: EXPERIMENTAL
Intervention: Balance training (BT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Isometric training (IT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 12914389

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resected patients
Number of subjects: 0
Study: 10102949

Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plain aspirin 75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7484589

Group type: EXPERIMENTAL
Intervention: Preoperative MR imaging at 1.5 T
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clinical criteria for biopsy site selection (no MR imaging)
Number of subjects: 25
Study: 2138163

Group type: EXPERIMENTAL
Intervention: Continuous suture + suction drain
Number of subjects: 93

Group type: COMPARATOR
Intervention: Simple suture at wide intervals of 4 cm
Number of subjects: 93
Study: 7432659

Group type: EXPERIMENTAL
Intervention: Alpha-mercaptopropionylglycine (1500 mg/day per os)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30224383

Group type: EXPERIMENTAL
Intervention: CNP520
Number of subjects: 0
Study: 27234460

Group type: EXPERIMENTAL
Intervention: Low polyunsaturated fat intake (1-4 g)
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat intake (6-12 g)
Number of subjects: 1672

Group type: COMPARATOR
Intervention: Adjustment for maximum wall thickness, hypertension, hyperlipidemia, and diabetes
Number of subjects: 1672
Study: 24794282

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy (PDT) combination therapy
Number of subjects: 255
Study: 22177195

Group type: EXPERIMENTAL
Intervention: Parents and Children Talking Together (PCTT)
Number of subjects: 78
Study: 21223653

Group type: EXPERIMENTAL
Intervention: Composite transplantation group (CT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 17661246

Group type: EXPERIMENTAL
Intervention: Information video on colonoscopy procedures and cleansing
Number of subjects: 162

Group type: COMPARATOR
Intervention: No video
Number of subjects: 162
Study: 16126926

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 26
Study: 12419644

Group type: EXPERIMENTAL
Intervention: New formulation of ticlopidine hydrochloride (250mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation Tiklid (250mg)
Number of subjects: 24
Study: 9859745

Group type: EXPERIMENTAL
Intervention: Gelatine (Unigraft)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Collagen (Hemashield)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Human albumin (USCI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 7621491

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 10 to 80 mg urea per piece, chewed for 10 minutes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two pieces of gum containing 20 mg urea each, chewed for 10 minutes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three pieces of gum containing 20 mg urea each, chewed one after the other (10 + 10 + 10 min).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional sugarless gum (control).
Number of subjects: 0
Study: 2504375

Group type: EXPERIMENTAL
Intervention: Restricted diet (avoiding milk and other dairy products, eggs, fish, peanuts, and soybeans) for mothers who breast fed (49 mothers)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Casein hydrolysate formula for infants not breast fed (43 infants)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Soy milk formula for infants not breast fed (41 infants)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Cows milk formula for infants not breast fed (40 infants)
Number of subjects: 221
Study: 331137

Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meglumine metrizoate
Number of subjects: 20
Study: 7226953

Group type: COMPARATOR
Intervention: Inhaled distilled water plus intramuscular (IM) saline solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inhaled A dose of atropine plus IM saline solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inhaled distilled water plus 0.35 mg IM atropine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inhaled A dose of atropine plus 0.35 mg IM atropine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inhaled double the A dose plus IM saline solution
Number of subjects: 6
Study: 30587857

Group type: EXPERIMENTAL
Intervention: EVIDENT II application and usual primary care counseling
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group (usual primary care counseling only)
Number of subjects: 597
Study: 29334921

Group type: EXPERIMENTAL
Intervention: Brief Social Behaviour and Network Therapy (B‐SBNT) + Treatment as Usual (TAU)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Personal Goal Setting (PGS) + Treatment as Usual (TAU)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 83
Study: 27189286

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU during screening, median doses of 2000 IU daily)
Number of subjects: 191
Study: 24219351

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for psychosis
Number of subjects: 56
Study: 23174592

Group type: EXPERIMENTAL
Intervention: SCIT plus ICS
Number of subjects: 100

Group type: COMPARATOR
Intervention: ICS only
Number of subjects: 100
Study: 20436046

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 17033909

Group type: EXPERIMENTAL
Intervention: Doxorubicin‐cisplatin (AP) chemotherapy
Number of subjects: 317

Group type: COMPARATOR
Intervention: Whole abdominal irradiation (WAI)
Number of subjects: 317
Study: 15702045

Group type: EXPERIMENTAL
Intervention: Single dose azithromycin (30 mg/kg)
Number of subjects: 313

Group type: COMPARATOR
Intervention: High dose amoxicillin (90 mg/kg/d, in 2 divided doses for 10 days)
Number of subjects: 313
Study: 11999665

Group type: EXPERIMENTAL
Intervention: Pravastatin (10-20 mg/day)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Conventional lipid-lowering drugs (fibrates, nicotinic acid, probucol)
Number of subjects: 1217
Study: 10458219

Group type: EXPERIMENTAL
Intervention: MA 160 mg/d (one tablet per day)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: MA 800 mg/d (five tablets per day)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: MA 1,600 mg/d (10 tablets per day)
Number of subjects: 368
Study: 7636280

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLUC)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AB)
Number of subjects: 41
Study: 2223648

Group type: EXPERIMENTAL
Intervention: Untreated stage A-CLL patients
Number of subjects: 309
Study: 350254

Group type: EXPERIMENTAL
Intervention: Various existing methods of allocation to treatment groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 31999146

Group type: EXPERIMENTAL
Intervention: Parenting Quality (PQ) from fathers
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Parenting Time (PT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Interparental Conflict (IPC)
Number of subjects: 141
Study: 29991662

Group type: EXPERIMENTAL
Intervention: Simulator workshop (G2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Theoretical explanation (G1)
Number of subjects: 62
Study: 27473843

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg for 12 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25342898

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg once daily (via Respimat(®)) combined with tiotropium 18 μg once daily (via HandiHaler(®))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily (via HandiHaler(®)) combined with placebo (via Respimat(®))
Number of subjects: 0
Study: 23773532

Group type: EXPERIMENTAL
Intervention: Concentric (80% of concentric‐eccentric 1RM, 4×7‐8)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Standard load eccentric only (80% of concentric‐eccentric 1RM, 4×12‐15 repetitions)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High load eccentric (80% of eccentric 1RM, 4×7‐8 repetitions)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 4
Study: 20035358

Group type: EXPERIMENTAL
Intervention: Baseline functional disability (Roland-Morris Disability Questionnaire scores)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Baseline fear of movement (Tampa Scale for Kinesiophobia scores)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Supervisor social support and duration of complaints
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Co-worker social support and pain radiation
Number of subjects: 273
Study: 18585908

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Supralingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sublingual active group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 41
Study: 16988729

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT) at a dose of 35-45 ml/kg/h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0
Study: 12798483

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study: 11032586

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 to 30 mg/d for >/= 2 years)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 345
Study: 9362144

Group type: EXPERIMENTAL
Intervention: Parental training and behavior-management training (6-week program)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Viewing family-related videotapes (6-week program)
Number of subjects: 30
Study: 8252955

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (0.2 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined oxitropium and fenoterol (0.2 mg and 0.4 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2938479

Group type: EXPERIMENTAL
Intervention: Assessment of Occupational Functioning (AOF) screening tool
Number of subjects: 83
Study: 31237939

Group type: EXPERIMENTAL
Intervention: Perioperative atrial fibrillation (POAF)
Number of subjects: 18117
Study: 28641369

Group type: EXPERIMENTAL
Intervention: Fibrinogen (quintile 5 vs. quintile 1)
Number of subjects: 27071

Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule‐1 (quintile 5 vs. quintile 1)
Number of subjects: 27071

Group type: EXPERIMENTAL
Intervention: N‐acetyl side‐chains of acute phase proteins
Number of subjects: 27071

Group type: EXPERIMENTAL
Intervention: High‐sensitivity C‐reactive protein
Number of subjects: 27071
Study: 27755488

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Number of subjects: 76

Group type: COMPARATOR
Intervention: Transversus abdominis plane block
Number of subjects: 76
Study: 24332238

Group type: EXPERIMENTAL
Intervention: Docetaxel plus active symptom control
Number of subjects: 168

Group type: COMPARATOR
Intervention: Active symptom control alone
Number of subjects: 168
Study: 22101223

Group type: EXPERIMENTAL
Intervention: Natural Spline Varying‐coefficient mixture model (NSV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditional Linear Model (CLM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard random‐effects model
Number of subjects: 0
Study: 20541825

Group type: EXPERIMENTAL
Intervention: Intensive glucose control with gliclazide MR-based regimen
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study: 18166300

Group type: EXPERIMENTAL
Intervention: Pelvic tenderness at 5 days
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Pelvic tenderness at 30 days
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Short-term markers (pelvic tenderness)
Number of subjects: 713
Study: 16173527

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diet restriction
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55